DiaMedica Therapeutics Inc.
DMAC | NASDAQ
$7.26
+$0.41 (+5.99%)
At close: Sep 21, 2026, 4:00 PM ET
$7.26
$0 (0.00%)
After-hours:
Sep 21, 2026, 4:10 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -34.4M | -26.68M | -21.27M | -14M | -13.65M | -12.7M |
Interest Income | n/a | 2.3M | n/a | n/a | n/a | n/a |
Pretax Income | -32.74M | -24.41M | -19.34M | -13.65M | -13.56M | -12.27M |
Net Income | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M | -12.29M |
Selling & General & Admin | 9.78M | 7.62M | 8.16M | 6.16M | 4.88M | 4.49M |
Research & Development | 24.61M | 19.06M | 13.11M | 7.84M | 8.77M | 8.21M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 34.4M | 26.68M | 21.27M | 14M | 13.65M | 12.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 34.4M | 26.68M | 21.27M | 14M | 13.65M | 12.7M |
Income Tax Expense | 28K | 30K | 43K | 28K | 28K | 27K |
Shares Outstanding (Basic) | 46.98M | 40.4M | 32.57M | 26.44M | 20.77M | 15.68M |
Shares Outstanding (Diluted) | 46.98M | 40.4M | 32.57M | 26.44M | 20.77M | 15.68M |
EPS (Basic) | -0.70 | -0.60 | -0.60 | -0.52 | -0.65 | -0.78 |
EPS (Diluted) | -0.70 | -0.60 | -0.60 | -0.52 | -0.65 | -0.78 |
EBITDA | -32.7M | -24.38M | -19.31M | -13.62M | -13.54M | -12.68M |
EBIT | -32.74M | -24.41M | -19.34M | -13.65M | -13.56M | -12.7M |
Depreciation & Amortization | 43K | 39K | 30K | 25K | 24K | 21K |
Add to Watchlist
Select watchlists to add or remove DMAC